Results 211 to 220 of about 91,763 (276)

Intravenous immunoglobulin as an adjunct to phototherapy in neonatal haemolytic disease: A systematic review and meta‐analysis

open access: yesTransfusion Medicine, EarlyView.
Abstract Phototherapy remains the first‐line treatment of haemolytic disease of the newborn (HDN), a potentially life‐threatening condition caused by maternal alloimmunisation. Intravenous immunoglobulin (IVIG) has been proposed as an adjunct to reduce the need for exchange transfusion (ET), a procedure associated with significant risks.
Megan Roberts   +11 more
wiley   +1 more source

AABB survey on directed blood donation practices

open access: yesTransfusion, EarlyView.
Abstract Background Standardized guidance regarding the processes for collecting directed blood donations (DBD) is lacking, leading to variable practices. This study assessed laboratory, clinical, and charging practices for DBD collection in the United States and Canada. Study Design and Methods An electronic survey was distributed to United States and
Nabiha H. Saifee   +6 more
wiley   +1 more source

Breakthrough Hemolysis in Paroxysmal Nocturnal Hemoglobinuria: Mechanistic Insights and Management Strategies

open access: yesTransfusion, EarlyView.
Abstract Background Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematopoietic stem cell disorder caused by somatic mutations in the PIGA gene, resulting in loss of glycosylphosphatidylinositol (GPI)‐anchored proteins, including the complement regulatory proteins, CD55 and CD59.
Ganesh Raman   +4 more
wiley   +1 more source

Mapping obstetric biobanks: A scoping review highlighting gaps in the study of alloimmunized pregnancies

open access: yesTransfusion, EarlyView.
Abstract Background Maternal red cell alloimmunization can cause hemolytic disease of the fetus and newborn (HDFN), yet prediction of disease severity remains limited. Biobanks that link pregnancy biospecimens with clinical and laboratory data could accelerate translational research; however, the landscape of relevant obstetric biobanks has not been ...
Orlin Chowdhury   +10 more
wiley   +1 more source

Implementation of soluble CD38 in blood crossmatching for patients on anti‐CD38 therapy: A single‐center experience

open access: yesTransfusion, EarlyView.
Abstract Background Human monoclonal (MoAb) anti‐CD38 antibodies, such as daratumumab, are used to treat diseases such as multiple myeloma. Because red blood cells (RBCs) express CD38, these MoAbs interfere with antibody screening and crossmatching in blood banks.
Ayda Javanbakht   +3 more
wiley   +1 more source

Rare subgroup of A phenotype-a case series. [PDF]

open access: yesAsian Biomed (Res Rev News)
Saidin NIS   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy